Evidence map›Paper›PMID 38672563›Full record

ArticleCancers2024

EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer.

Ann M Chan, Brian Aguirre, Lucia Liu, Vei Mah, Justin M Balko, Jessica Tsui, Navin P Wadehra, Neda A Moatamed, Mahdi Khoshchehreh, Christen M Dillard and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Ann M ChanDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Brian AguirreDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0009-0001-7572-0171
Lucia LiuDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Vei MahDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Justin M BalkoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Jessica TsuiDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Navin P WadehraDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Neda A MoatamedDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-9986-8058
Mahdi KhoshchehrehDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Christen M DillardDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-7218-9960
Meagan KiyoharaDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Yahya ElshimaliDivision of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, 1720 East 120th Street, Los Angeles, CA 90059, USA.
Helena R ChangDivision of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0001-6939-4499
Diana Marquez-GarbanJonsson Comprehensive Cancer Center, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0002-4693-3063
Nalo HamiltonJonsson Comprehensive Cancer Center, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0002-6717-8079
Richard J PietrasDivision of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, 1720 East 120th Street, Los Angeles, CA 90059, USA.ORCID 0000-0002-2846-3192
Lynn K GordonUCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
Madhuri WadehraDepartment of Pathology Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0001-8514-2021
University of California, Los Angeles · USCharles R. Drew University of Medicine and Science · USVanderbilt University Medical Center · US

Funding

Using EMP2 for Image Guided Drug Delivery for Breast CancerR01CA163971 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OLAFSEN, TOVE, WADEHRA, MADHURI · 2012 to 2016
$1.6M
NIH HHS NIH U54-CA-14391NIH HHS R01 CA163971
6 · The paper itself

Abstract

Breast cancer (BC) remains among the most commonly diagnosed cancers in women worldwide. Triple-negative BC (TNBC) is a subset of BC characterized by aggressive behavior, a high risk of distant recurrence, and poor overall survival rates. Chemotherapy is the backbone for treatment in patients with TNBC, but outcomes remain poor compared to other BC subtypes, in part due to the lack of recognized functional targets. In this study, the expression of the tetraspan protein epithelial membrane protein 2 (EMP2) was explored as a predictor of TNBC response to standard chemotherapy. We demonstrate that EMP2 functions as a prognostic biomarker for patients treated with taxane-based chemotherapy, with high expression at both transcriptomic and protein levels following treatment correlating with poor overall survival. Moreover, we show that targeting EMP2 in combination with docetaxel reduces tumor load in syngeneic and xenograft models of TNBC. These results provide support for the prognostic and therapeutic potential of this tetraspan protein, suggesting that anti-EMP2 therapy may be beneficial for the treatment of select chemotherapy-resistant TNBC tumors.

Indexed as

biomarkerchemotherapyepithelial membrane protein 2triple-negative breast cancer

Identifiers

PMID38672563
PMCPMC11048488
OpenAlexW4394750188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.